Another study demonstrated that SHP1 inhibits the proliferation and apoptosis of LNCaP cells as well as IL-6-treated offspring LNCaP-IL6+ cell lines, suggesting that SHP1 may be a therapeutic target for PCa (Tassidis et al., 2010b). Here, IL6 is linked to posterior cortical atrophy.